PeptiDream Inc. announced the nomination of the second targeted peptide Radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio Inc., ("RayzeBio"), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs. The development candidate is a novel first-in-class macrocyclic peptide- radioisotope (RI) conjugate against Glypican-3 ("GPC3") expressed in liver cancers. Liver cancer is a leading cause of death global, according for over 800,000 deaths annually.

The peptide-RI development candidate was discovered using PeptiDream's proprietary Peptide Discovery Platform System (PDPS) and demonstrated potent and selective GPC3 binding, rapid cellular internalization, and sustained tumor specific uptake and anti-tumor efficacy in pre-clinical models at RayzeBio. RayzeBio intends to present initial preclinical data at the EASL Liver Cancer Summit in Estoril, Portugal on April 20. 2023.

PeptiDream and RayzeBio have an ongoing multi- program collaboration, initiated in August 2020, to screen and identify novel peptide binders against tumor antigens for the targeted delivery of radioisotopes.